New Trial Offers PBS Relief for Patients

March 20, 2019| Healthcare News /

Image: Epworth HealthCare Chief Medical Officer Luis Prado, Professor of Medicine Miles Prince, Minister for Health Greg Hunt, Executive Director Freemasons and Richmond Nicole Waldron and Group CEO Lachlan Henderson at the recent Pharmaceutical Benefits Scheme (PBS) announcement at Epworth Richmond.

An Australian global clinical trial led by Professor Miles Prince AM has seen a breakthrough drug being added to the Pharmaceutical Benefits Scheme (PBS).

Federal Minister for Health Greg Hunt announced recently at Epworth Richmond that crucial medicines for Cancer, Parkinson's and motor neurone disease will be listed on the scheme as at 1 April 2019.

The Federal Government will invest $19 million to broaden the PBS listing of Adcetris® to include the treatment of a rare cancer called cutaneous T-cell lymphoma, Xadago® listed to treat Parkinson’s disease and Teglutik® for the treatment of motor neurone disease.

Minister Greg Hunt & Epworth Nurse Unit Manager, Nicola Ashford

Minister Greg Hunt & Epworth Nurse Unit Manager, Nicola Ashford

Adcetris® as a treatment for skin lymphoma was studied as a part of a large international clinical trial. This study was published in the Lancet, with Professor Prince as lead author.

Professor Miles Prince said that after 6 years hard work, it was astounding that Adcetris® could now be prescribed to patients.

Adcetris® has proven to be effective and well tolerated in patients who require systemic therapy to control their disease. This is an important treatment option for Australian patients who are at a difficult stage of their disease.

I am proud to be part of the Epworth team which is absolutely the best place to receive the most innovative, leading options in care, which will give patients the best hope of successful treatment.

Thanks for your ongoing support for the Epworth and for allowing us to do what we do best.
— Prof Miles Prince, Clinical Haematologist, Epworth HealthCare

An internationally recognised haematologist, the Director of Molecular Oncology and Cancer Immunology at Epworth HealthCare, Professor Prince has been involved in numerous clinical trials of new therapies for blood cancers and a part of more than 100 clinical trials involving myeloma, lymphoma, leukaemia, transplantation and supportive care.

He has an incredible team of people working on different trials who are the next generation of great innovators in treatment.

As a part of the announcement, the Minister toured the oncology ward at Epworth Richmond to meet with some Epworth patients and was joined by patients and their families in the courtyard afterwards.

Group CEO Lachlan Henderson, Executive Director Freemasons and Richmond Nicole Waldron and Chief Medical Officer Luis Prado, representatives from the pharmaceutical companies as well as Rare Cancer Australia and Lymphoma Australia were also present.



Epworth

Join the conversation on The Village



June 17, 2019| Health and Wellbeing/

When Period Pain Strikes Again

We caught up with Dr Kent Kuswanto, Epworth obstetrician and gynaecologist to talk all things periods.

June 13, 2019| Our Community/

Team Recipes - Super Moist Gluten Free Banana Bread

Recipes brought to you by the Epworth team. You can’t stop at one slice and you’ll never know it’s gluten free! Slice & serve warm.

June 11, 2019| Our Community/

First Birthday for Epworth Cousins

It’s been a year since we’ve been following sisters Alex and Jane’s bubs - Charlotte and Lola. It’s been a year since they both gave birth to their daughters, one at Epworth Freemasons and the other at Epworth Geelong. Let’s find out how life has changed since then.

June 4, 2019| Health and Wellbeing/

Ovarian Cysts

An ovarian cyst is a fluid filled sac or pouch which forms on the ovary. Ovarian cysts, in most cases are harmless and resolve on their own. If the cyst is cancerous, it requires medical intervention. Ovarian cysts are common in women of childbearing age.

May 21, 2019| Health and Wellbeing/

Catering for Someone with a Food Allergy

With 1 in 10 infants now developing a food allergy, being conscious of what you are buying and how you prepare food is more important than ever.